The Israel-based company reported that it will begin the commercial launch for CGuard in South Africa immediately.
“We are extremely pleased with the opportunity to offer CGuard EPS in the South African market. We were approached by some of our key customers in the Vascular Surgery, Interventional Neurology and Interventional Cardiology field who had learned about CGuard EPS through conferences and publications and wanted us to make it available in South Africa,” Craig Goodburn, managing member of Torque Medical, said in prepared remarks. “We see CGuard EPS as a key tool for fighting stroke caused by carotid artery disease in our country.”
“As awareness of CGuard among vascular surgeons, interventional neurologists, and cardiologists continues to grow through real-world experience, word-of-mouth, conference presentations, and publications, we are seeing more and more ‘pull-through’ demand in which treating physicians initiate contact with local distributors to make CGuard available in their market, such as what occurred in South Africa,” InspireMD CEO James Barry said.
“In our view, this is a very significant validation of our technology and a clear reflection of CGuard’s clinical advantages relative to both conventional carotid stents and carotid endarterectomy,” Barry added.
Last year, InspireMD won regulatory approval for its CGuard system and MGuard Prime device in Ecuador.